Logo
x

Search

Subscribe Now

Bluebird Bio

bluebird bio Reports the US FDA Acceptance of BLA for lovotibeglogene autotemcel to Treat Sickle Cell Disease in Patients Aged ≥12 Years

bluebird bio Reports the US FDA Acceptance of BLA for lovotibeglogene autotemcel to Treat Sickle Cell Disease in Patients Aged ≥12...

  • June 21, 2023
bluebird bio’s Zynteglo (betibeglogene autotemcel) Receives the US FDA’s Approval for the Treatment of Beta-Thalassemia

bluebird bio’s Zynteglo (betibeglogene autotemcel) Receives the US FDA’s Approval for the Treatment of Beta-Thalassemia

  • August 18, 2022
Bluebird bio Reports US FDA Acceptance of BLA for Priority Review of Lenti-D (elivaldogene autotemcel) for Cerebral Adrenoleukodystrophy

Bluebird bio Reports US FDA Acceptance of BLA for Priority Review of Lenti-D (elivaldogene autotemcel) for Cerebral Adrenoleukodys...

  • December 20, 2021
PharmaShots Interview: bluebird bio's Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy

PharmaShots Interview: bluebird bio's Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy

  • June 4, 2021
BMS and bluebird bio Report the US FDA's Acceptance of Idecabtagene Vicleucel's BLA for Priority Review to Treat Multiple Myeloma

BMS and bluebird bio Report the US FDA's Acceptance of Idecabtagene Vicleucel's BLA for Priority Review to Treat Multiple Myeloma

  • September 23, 2020
PharmaShots Weekly Snapshot (May 11-15, 2020)

PharmaShots Weekly Snapshot (May 11-15, 2020)

  • May 18, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.